Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD/MAD Study of MEB-1170 in Healthy Subjects
NCT05748119Phase 1Unknown
- Sponsor
- Mebias Discovery
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEB-1170 in pain (10 arms), sponsored by Mebias Discovery. Primary endpoint: Safety and Tolerability of Single and Multiple Ascending Doses. Status: unknown.
02
Drugs
MEB-1170
03
Conditions
pain
Beyond the preview
Go deeper on NCT05748119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748119.